Literature DB >> 12445304

The role of CD55 in protecting the tumour environment from complement attack.

J Morgan1, I Spendlove, L G Durrant.   

Abstract

CD55 is a complement regulatory protein expressed by cells to protect them from bystander killing by complement. CD55 is over-expressed 2-100-fold on tumour cells and is deposited in large amounts within tumour matrix. Vascular endothelial growth factor (VEGF) produced by tumours to stimulate angiogenesis, also up-regulates endothelial cell surface expression of CD55 and stimulates the release of matrix degrading metalloproteinases. This study investigated the effects of VEGF on CD55 deposition into matrix and the release of CD55 by metalloproteinases. In contrast to inflammatory cytokines, CD55 was up-regulated by VEGF at the cell surface and within the extracellular matrix (ECM). Interestingly, human umbilical vein endothelial cells (HUVEC) exposed to VEGF released similar amounts of CD55 into the ECM as a tumour cell line expressing 50-fold higher level of CD55 on its cell surface. Furthermore, in contrast to earlier studies, both tumour and HUVEC-derived CD55 was functionally active. However, in contrast to papain that degrades CD55, and collagenase that fails to release CD55, MMP-7 released intact CD55 from ECM. This suggests that it may have a further role to play in protecting cells during inflammation and invasion.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12445304     DOI: 10.1034/j.1399-0039.2002.600303.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  12 in total

1.  LEUKOCYTE-EPITHELIAL INTERACTIONS: A DOUBLE-EDGED SWORD THAT PROTECTS AND INJURES DURING HEALTH AND DISEASE.

Authors:  Charles A Parkos
Journal:  Trans Am Clin Climatol Assoc       Date:  2022

2.  Role of complement activation in obliterative bronchiolitis post-lung transplantation.

Authors:  Hidemi Suzuki; Mark E Lasbury; Lin Fan; Ragini Vittal; Elizabeth A Mickler; Heather L Benson; Rebecca Shilling; Qiang Wu; Daniel J Weber; Sarah R Wagner; Melissa Lasaro; Denise Devore; Yi Wang; George E Sandusky; Kelsey Lipking; Pankita Pandya; John Reynolds; Robert Love; Thomas Wozniak; Hongmei Gu; Krista M Brown; David S Wilkes
Journal:  J Immunol       Date:  2013-09-16       Impact factor: 5.422

Review 3.  The dual role of complement in cancer and its implication in anti-tumor therapy.

Authors:  Ioannis Kourtzelis; Stavros Rafail
Journal:  Ann Transl Med       Date:  2016-07

4.  Inhibition of decay-accelerating factor (CD55) attenuates prostate cancer growth and survival in vivo.

Authors:  Robert D Loberg; LaShon L Day; Rodney Dunn; Linda M Kalikin; Kenneth J Pienta
Journal:  Neoplasia       Date:  2006-01       Impact factor: 5.715

5.  Prostaglandin E2 and Krüppel-like transcription factors synergistically induce the expression of decay-accelerating factor in intestinal epithelial cells.

Authors:  Jinyi Shao; Vincent W Yang; Hongmiao Sheng
Journal:  Immunology       Date:  2008-04-16       Impact factor: 7.397

Review 6.  The role of complement in tumor growth.

Authors:  Ruben Pio; Leticia Corrales; John D Lambris
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

7.  IL-17A promotes the migration and invasiveness of cervical cancer cells by coordinately activating MMPs expression via the p38/NF-κB signal pathway.

Authors:  Minjuan Feng; Yidong Wang; Kunlun Chen; Zhuoqiong Bian; Qing Gao
Journal:  PLoS One       Date:  2014-09-24       Impact factor: 3.240

Review 8.  Beyond the Role of CD55 as a Complement Component.

Authors:  So Hee Dho; Jae Cheong Lim; Lark Kyun Kim
Journal:  Immune Netw       Date:  2018-02-20       Impact factor: 5.851

9.  CD55 is a HIF-2α marker with anti-adhesive and pro-invading properties in neuroblastoma.

Authors:  F Cimmino; M Avitabile; L Pezone; G Scalia; D Montanaro; M Andreozzi; L Terracciano; A Iolascon; M Capasso
Journal:  Oncogenesis       Date:  2016-04-04       Impact factor: 7.485

10.  Activation of the complement cascade enhances motility of leukemic cells by downregulating expression of HO-1.

Authors:  A Abdelbaset-Ismail; S Borkowska-Rzeszotek; E Kubis; K Bujko; K Brzeźniakiewicz-Janus; L Bolkun; J Kloczko; M Moniuszko; G W Basak; W Wiktor-Jedrzejczak; M Z Ratajczak
Journal:  Leukemia       Date:  2016-07-25       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.